A Phase 1/2 interventional study of Sorafenib in HCC and Hepatocellular Carcinoma, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-30.
Sponsored by Assiut University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.
Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 22nd largest by planned enrollment, is the only one that started in 2023, is one of 13 in phase 1/2, and was the 104th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–99
Zhejiang Haichang Biotech Co., Ltd. · Sites in China, Hong Kong
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages up to 30
Humanity & Health Medical Group Limited · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 59 · Phase 3 17 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 44 across the 104 interventional studies. Of the 71 that completed or were terminated, 24 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 104 have an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
19 studies in Carcinoma, Hepatocellular by Assiut University: 10 open now, 10 under way, none of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 19 studies in Carcinoma, Hepatocellular by Assiut University, this one is one of 3 that started in 2023, is the only one in phase 1/2, and was the 13th registered.
Assiut University’s Carcinoma, Hepatocellular studies by the year they started, since 2015.
4 of the studies testing sorafenib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT06309485Zhejiang Haichang Biotech Co., Ltd.Phase 2 Study of WGI-0301 for Advanced HCC | 2026-12 |
| NCT05669339University of FloridaAD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | 2027-04 |
| NCT01840592Memorial Sloan Kettering Cancer CenterSorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, from their registry updates:
Among Assiut University’s 19 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sorafenib 200 - 400 mg twice daily
Drug: Sorafenib
Sorafenib Tablets (200 -400 mg) twice daily
Vascular Endothelial Growth Factor A (VEGFA) genotyping
Genetic polymorphism of VEGFA
Time frame: At Baseline, 3 month, and 6 month after treatment.
Kinase insert domain receptor (KDR) genotyping
Genetic polymorphism of KDR
Time frame: At Baseline, 3 month, and 6 months after treatment.
Tumor markers
Determination of serum Alpha-Fetoprotein, AFP-L3
Time frame: At Baseline, 3 month, and 6 month after treatment.
Complete blood culture
Determination of hemoglobin concentration
Time frame: At Baseline 3 month, and 6 months after treatment.
Kidney function tests
Determination of Serum creatinine concentration
Time frame: At Baseline 3 month, and 6 months after treatment.
Liver function tests.
Determine serum level of ALT and AST
Time frame: At Baseline 3 month, and 6 months after treatment.
Safety outcome
Incidence of side effects such as (diarrhea, anorexia, nausea, vomiting, hand and foot syndrome)
Time frame: At Baseline, 3 month, and 6 months after treatment.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.
Of 136 phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 76. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sorafenib